Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of clostridium difficile infections in allogeneic stem cell transplant
Hematology, Oncology and Stem Cell Therapy. 2018; 11 (4): 233-240
em Inglês
| IMEMR
| ID: emr-201845
ABSTRACT
Objective/background:
Clostridium difficile infection [CDI] is a potential complication during hematopoietic stem cell transplantation [HSCT], and no specific recommendations exist regarding treatment of CDI in allogeneic SCT patients. Use of metronidazole and oral vancomycin has been associated with clinical failure. Fidaxomicin has previously been found noninferior to the use of oral vancomycin for the treatment of CDI, and no studies have compared the use of oral
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Idioma:
Inglês
Revista:
Hematol. Oncol. Stem Cell Ther.
Ano de publicação:
2018
Similares
MEDLINE
...
LILACS
LIS